Authors
Stefan Zeuzem, Jean-Michel Pawlotsky, Esther Lukasiewicz, Michael Von Wagner, Ioannis Goulis, Yoav Lurie, Elia Gianfranco, Jan-Maarten Vrolijk, Juan I Esteban, Christophe Hezode, Martin Lagging, Francesco Negro, Alexandre Soulier, Elke Verheij-Hart, Bettina Hansen, Ronen Tal, Carlo Ferrari, Solko W Schalm, Avidan U Neumann, DITTo-HCV Study Group
Publication date
2005/8/1
Journal
Journal of hepatology
Volume
43
Issue
2
Pages
250-257
Publisher
Elsevier
Description
BACKGROUND/AIMS
The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response.
METHODS
Serum HCV-RNA was frequently quantified in patients with chronic hepatitis C (n=270) treated with peginterferon alfa-2a (180μg/week) and ribavirin (1000–1200mg/day). After 6 weeks patients were classified as rapid (RVR), slow (SPR), flat (FPR), or null responders (NUR) and randomized within each viral kinetic class to continue therapy either with an individualized or standard regimen. Individualized therapy comprised peginterferon monotherapy (48 weeks) or shorter combination therapy (24 weeks) for RVR, triple therapy with histamine (1mg/day) (48 weeks) or prolonged combination therapy (72 weeks) for SPR, triple therapy for FPR, and high-dose peginterferon (360μg/week) plus ribavirin for NUR patients.
RESULTS
Patients were categorized …
Total citations
Scholar articles
S Zeuzem, JM Pawlotsky, E Lukasiewicz… - Journal of hepatology, 2005